Histone Specific Neutra™ Antibody Products

Are you grappling with challenges in chromatin biology studies, such as inconsistent detection of histone modifications, prolonged drug development cycles, or insufficient tools for epigenetic targeting? Creative Biolabs' histone-specific Neutra™ antibody products use advanced recombinant antibody engineering and high-throughput validation to provide unparalleled specificity. This enables precise investigation of histone dynamics and accelerates treatment discovery.

Introduction to Histone

Histones are evolutionarily conserved alkaline proteins integral to eukaryotic chromatin architecture. Comprising five major classes (H1, H2A, H2B, H3, and H4), histones organize DNA into nucleosomes, regulating genome accessibility and epigenetic inheritance. Post-translational modifications (PTMs)—such as acetylation, methylation, phosphorylation, and ubiquitination—dictate chromatin remodeling, transcriptional activation/repression, and DNA repair processes.

• Structural Complexity and Diversity

The canonical nucleosome core particle comprises two copies each of H2A, H2B, H3, and H4, forming an octamer around which 147 base pairs of DNA are wrapped. Linker histone H1 stabilizes higher-order chromatin structures. Beyond their structural roles, histone variants (e.g., H3.3, H2A.Z) and PTMs create a dynamic "histone code" that governs cell-specific gene expression. For instance, H3K4me3 marks active promoters, while H3K27me3 is linked to transcriptional silencing.

Fig.1 Effect of H3.1/H3.3-K27M mutation in tumor progression.¹

• Signaling Pathways and Epigenetic Crosstalk

Histone modifications intersect with critical cellular pathways. The interplay between histone acetylation and HDAC (histone deacetylase)/HAT (histone acetyltransferase) enzymes modulates Wnt/β-catenin signaling, impacting cell proliferation. Similarly, DNA damage responses rely on γH2AX (phosphorylated H2AX) to recruit repair complexes. Dysregulation of these pathways is linked to oncogenesis and neurodegenerative disorders.

• Disease Relevance

Aberrant histone modifications drive pathologies such as cancer, where global hypomethylation or hypermethylation of tumor suppressor genes disrupts genomic stability. Leukemias and lymphomas frequently harbor mutations in histone methyltransferases (e.g., EZH2). In Alzheimer's disease, altered H4K16 acetylation correlates with synaptic dysfunction. Autoimmune diseases like lupus exhibit abnormal histone citrullination, triggering autoantibody production.

Applications of Anti-Histone Neutralizing Antibodies

• Deciphering Epigenetic Mechanisms in Disease

Antibodies enable precise detection of histone PTMs in cancer biopsies, neural tissues, and immune cells. For example, quantifying H3K27me3 levels identifies aggressive tumor subtypes, while monitoring H4 acetylation elucidates neuroprotective pathways in neurodegeneration.

• Biomarker Discovery and Diagnostic Development

Histone modification patterns in circulating nucleosomes function as non-invasive biomarkers. Antibodies targeting H3Cit (citrullinated H3) aid in early diagnosis of rheumatoid arthritis, while H3K36me2 detection predicts chemotherapy resistance in solid tumors.

• Therapeutic Target Validation

Screen histone-modifying enzyme inhibitors (e.g., HDAC inhibitors) using antibodies to assess on-target effects. In CAR-T cell therapy, modulating histone acetylation via HDAC6 inhibitors enhances antitumor activity, validated by H3K9ac staining.

• Epigenetic Drug Development

High-content screening with Antibodies accelerates identification of small molecules targeting BET bromodomains or EZH2. For instance, inhibitors of H3K79 methylation are in clinical trials for MLL-rearranged leukemias.

• Clinical Trial Support

Standardize pharmacodynamic assessments in epigenetic therapies. Antibodies against H3K27ac track enhancer activation in patients treated with BET inhibitors, correlating with therapeutic efficacy.

Our Anti-Histone Antibody Products

Creative Biolabs provides histone-specific Neutra™ antibody products that combine unmatched specificity, reproducibility, and scalability to promote innovation in epigenetics and drug discovery. Whether exploring chromatin dynamics, developing diagnostics, or validating novel therapeutics, our solutions empower researchers to achieve rapid, reliable results. Our histone-specific antibodies have undergone extensive validation to identify PTMs, isoforms, and variants across species and applications. Our products include:

- Pan-specific antibodies recognizing conserved epitopes (e.g., H3 C-terminal domains).

- Modification-specific antibodies for PTMs such as H3K9ac (activation markers) and H3K27me3 (repressive marks).

- ChIP-grade antibodies optimized for chromatin immunoprecipitation, enabling genome-wide mapping of histone marks.

With batch-to-blot consistency and >95% specificity, these antibodies streamline epigenetic profiling, drug screening, and mechanistic studies.

Contact our scientific team today to discuss your project requirements.

REFERENCE

1. Lai, Po Man, Xiaoxiang Gong, and Kui Ming Chan. "Roles of Histone H2B, H3 and H4 Variants in cancer development and prognosis." International Journal of Molecular Sciences 25.17 (2024): 9699. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms25179699